VanEck Vectors Biotech ETF (BBH)
180.00
+1.00 (+0.56%)
USD |
Mar 01, 11:52
Price Chart
Key Stats
Customize
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.35% | 0.13% | 495.47M | 14836.63 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.34% | 40.00% | 32.66M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | VanEck |
| Prospectus Benchmark Index | |
| MVIS US Listed Biotech 25 NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Hao-Hung (Peter) Liao | 9.13 yrs |
| Guo Hua (Jason) Jin | 3.00 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
30
32.66M
-4.597B
Category Low
7.682B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of January 31, 2021
Performance Versus Category
As of February 26, 2021. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
Edit comparables
As of February 26, 2021.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Amgen Inc | 11.95% | 227.31 | 1.06% |
| Illumina Inc | 6.26% | 449.00 | 2.18% |
| Gilead Sciences Inc | 6.11% | 62.25 | 1.38% |
| Alexion Pharmaceuticals Inc | 5.42% | 153.49 | 0.48% |
| Biogen Inc | 5.30% | 274.39 | 0.55% |
| IQVIA Holdings Inc | 5.30% | 193.93 | 0.59% |
| Novavax Inc | 5.12% | 234.98 | 1.62% |
| Moderna Inc | 4.78% | 147.86 | -4.49% |
| Guardant Health Inc | 4.57% | 150.70 | 2.39% |
| Vertex Pharmaceuticals Inc | 4.44% | 211.96 | -0.28% |
News
Headline
Wire
Time (ET)
Business Wire
11/22 17:15
Business Wire
11/16 17:52
Basic Info
| Investment Strategy | |
| The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Unaligned |
| Fund Owner Firm Name | VanEck |
| Prospectus Benchmark Index | |
| MVIS US Listed Biotech 25 NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Hao-Hung (Peter) Liao | 9.13 yrs |
| Guo Hua (Jason) Jin | 3.00 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (3-1-21) | 0.34% |
| 30-Day SEC Yield (2-24-21) | Upgrade |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 26.66 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of February 25, 2021
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 12/20/2011 |
| Last Annual Report Date | 9/30/2020 |
| Last Prospectus Date | 2/1/2021 |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)
Business Wire
11/22 17:15
Business Wire
11/16 17:52